Rhone-poulenc Rorer S.a.

Aventis Pharma S.a.

Aventis Pharmaceuticals Inc.

Sanofi

Sanofi-aventis

Herve Bouchard

Jean-Dominique Bourzat

Alain Commercon

Alain Commercedillaon

Michael L Edwards

Andrew David Morley

Augustin Hittinger

Conception Nemecek

Tahir Nadeem Majid

Paul Joseph Cox

Charles J Gardner

Brian L Pedgrift

Shelley Amendola

Timothy A Gillespy

Christopher D Edlin

Frank Halley

Stephanie Deprets

Francois Clerc

Laurence Gauzy

Ravi V J Chari

Hartmut Strobel

Daniel J Tavares

Kurt Ritter

Jean-Luc Malleron

Didier Babin

Dominique Lesuisse

Sven Ruf

Jean Bouquerel

Youssef El-Ahmad

Vincent Mikol

Marcel Patek

Dominique Damour

John Charles Reader

Daniel Achard

Bruno Filoche

Jacques Mauger

Serge Grisoni

Fahad A Al-Obeidi

Mark Gabriel Palermo

Anil Nair

Michael Cherry

Ingrid Sassoon

Michael R Myers

Fabienne Parker

Claudia Fromond

Dorothea Kominos

Chantal Carrez

Thomas Faitg

Nawaz Mohammed Khan

Justine Yeun Quai Lai

Olivier Houille

Lloyd J Payne

Alain Le-Brun

Didier Bénard

Daniel N A Bezard

Daniel Bond

Greg Harlow

Robert Yongxin Zhao

Michel Tabart

Francis Blanche

Wei Li

Beatrice Cameron

Patrick Mailliet

Fabrice Viviani

Jidong Zhang

Fabienne Thompson

Tarik Dabdoubi

Catherine Souaille

Bernard Baudoin

Marie-Pierre Cherrier

Marie-Priscille Brun

Laurence Gauzy-Lazo

Alexey Rak

Jean-Pierre Pulicani

Pierre-Francois Berne

Paul Ferrari

Martine Zucco

Yonghong Deng

Teresa Damiano

Stephanie D Deprets

Corinne Terrier

Jean-Dominique Boureat

The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.

Antibodies that specifically bind to the EphA2 receptor

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses.

Cytotoxic agents comprising new tomaymycin derivatives

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Leptomycin derivatives having a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody are disclosed. The therapeutic use of such leptomycin derivative conjugates is also described; such conjugates have therapeutic use because they can deliver cytotoxic leptomycin derivatives to a specific cell population in a targeted fashion.

Leptomycin derivatives

A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, Rand Rare as defined in the specification.

Pharmacological uses of azetidine derivatives

Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology. 

[object Object]

The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.

Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

The present invention relates to pharmaceutical compositions containing, as active ingredient, a compound of formula: in which Rrepresents a radical &#x2014;NHCORor &#x2014;N(R)&#x2014;Y&#x2014;R, Y is CO or SO, Rrepresents a radical -alk-SO&#x2014;R, -alk-SO&#x2014;CH&#x2550;CH&#x2014;Ror Het substituted with &#x2014;SO&#x2014;Ror a phenyl radical substituted with &#x2014;SO&#x2014;Ror -alk-SO&#x2014;R, Rrepresents a hydrogen atom or an alkyl radical, Rrepresents a phenylalkyl, Het or Ar radical, to the novel derivatives of formula (I) and to their preparation, as well s to their use in treating various disorders of the nervous system.

Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compositions which comprise them

Taxoids, preparation thereof and pharmaceutical compositions containing

Growing community of inventors

Thiais, France

Herve Bouchard